Vireo Growth (VREOF) Non-Current Deferred Tax Liability (2025 - 2026)

Vireo Growth (VREOF) posted Non-Current Deferred Tax Liability of $8.1 million for Q1 2026, down 20.59% sequentially from $10.2 million in Q4 2025.

Vireo Growth (VREOF) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends

Vireo Growth has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $8.1 million in Q1 2026.

Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (changed N/A YoY) and the FY2025 annual result came in at $10.2 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability eased to $8.1 million in Q1 2026 per VREOF's latest filing, from $10.2 million in the prior quarter.
Over five years, Non-Current Deferred Tax Liability peaked at $10.2 million in Q4 2025 and troughed at $8.1 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.78 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.71 Bn	22.91 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.59 Bn	683.80 Mn
6	Viatris	18.72 Bn	17.83 Bn	1.46 Bn
7	Neurocrine Biosciences	15.57 Bn	15.18 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.97 Bn	-
10	Vireo Growth	487.39 Mn	345.09 Mn	95.30 Mn

Download Data